Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATH-063 in Relapsed/Refractory Moderately to Severely Active Ulcerative Colitis
NCT07513181Phase 2Recruiting
- Sponsor
- Athos Therapeutics
- Start
- Apr 2026
- Primary completion
- Dec 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ATH-063 in ulcerative colitis (UC), sponsored by Athos Therapeutics. Started Apr 2026; status: recruiting.
02
Drugs
ATH-063
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT07513181.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07513181.